Tertiary lymphoid structures-driven immune infiltration patterns and their association with survival in neuroblastoma
Xuelian Liu, Jian Deng, Bingqing Yu, Jiaxiong Tan, Xiaoliang Lu, Minmin Zhang
TL;DR
This study identifies a 6-gene signature linked to tertiary lymphoid structures that predicts better survival in neuroblastoma patients and highlights CD200 as a potential treatment target.
Contribution
A novel 6-gene TLS signature is proposed as a prognostic biomarker for neuroblastoma, with CD200 identified as a potential therapeutic target.
Findings
A 6-gene TLS signature (CCL2, CCL4, CCL21, CD200, CXCR3, IGSF6) correlates with improved survival in neuroblastoma patients.
The low-TLS risk group showed better event-free and overall survival, with higher immune cell infiltration, especially cytotoxic T cells.
CD200 downregulation reduces NB cell invasiveness and migration, suggesting its potential as a therapeutic target.
Abstract
Neuroblastoma (NB), a diverse childhood cancer, needs better prognostic markers for personalized treatment. The current clinical risk stratification system does not fully explain the high heterogeneity of tumor patients. Tertiary lymphoid structures (TLS), key in tumor immunity, may serve as new biomarkers, but their impact on NB prognosis is unclear. We combined transcriptome data from NB cohorts GSE49710 and GSE62564, analyzing 37 TLS-related genes. A prognostic signature (CMLS) was created using machine learning and validated with Kaplan-Meier and receiver operating characteristic (ROC) curves. We also studied immune infiltration and gene expression patterns in NB tissues using single-cell sequencing and quantitative real-time polymerase chain reaction (qRT-PCR). A 6-gene TLS signature predicted better survival in NB patients. High levels of CCL2, CCL4, CCL21, CD200, CXCR3, and…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNeuroblastoma Research and Treatments · Immune cells in cancer · Cancer Immunotherapy and Biomarkers